Active Ingredient History
Dabigatran ethyl ester is a one of the intermediate, which is formed during metabolic reactions from dabigatran etexilate. Dabigatran ethyl ester forming under the action of intestinal carboxylesterase 2 (CES2) further is hydrolyzed by CES1 with formation of active drug, thrombin inhibitor, dabigatranand. Dabigatran ethyl ester is a much stronger inhibitor of ribosyldihydronicotinamide dehydrogenase, than dabigatran. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Coronary Syndrome (Phase 4)
Alzheimer Disease (Phase 1)
Aneurysm (Phase 3)
Angina, Stable (Phase 4)
Angina, Unstable (Phase 4)
Anticoagulants (Phase 4)
Antithrombins (Phase 4)
Aortic Valve Disease (Phase 4)
Aortic Valve Stenosis (Phase 4)
Appendix (Phase 4)
Arthroplasty, Replacement (Phase 4)
Arthroplasty, Replacement, Hip (Phase 3)
Arthroplasty, Replacement, Knee (Phase 3)
Atherosclerosis (Phase 4)
Atrial Fibrillation (Phase 4)
Atrial Flutter (Phase 4)
Blood Coagulation Disorders (Phase 1)
CADASIL (Phase 2)
Cardiac Catheterization (Phase 2)
Cardiovascular Diseases (Phase 1)
Cerebral Hemorrhage (Phase 3)
Cerebral Intraventricular Hemorrhage (Phase 3)
Cerebrovascular Disorders (Phase 3)
Cognition Disorders (Phase 4)
Cognitive Dysfunction (Phase 1)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Dementia (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Drug Interactions (Early Phase 1)
Drugs, Investigational (Early Phase 1)
Electric Countershock (Phase 3)
Foramen Ovale, Patent (Phase 3)
General Surgery (Phase 3)
Healthy Volunteers (Phase 2/Phase 3)
Heart Diseases (Phase 4)
Heart Valve Diseases (Phase 4)
Heart Valve Prosthesis (Phase 2)
Hematoma (Phase 3)
Hematoma, Subdural (Phase 3)
Hemorrhage (Phase 4)
Hepatic Insufficiency (Phase 1)
Hypertrophy, Left Ventricular (Phase 4)
Intracranial Hemorrhage, Hypertensive (Phase 3)
Intracranial Hemorrhages (Phase 3)
Ischemia (Phase 4)
Ischemic Attack, Transient (Phase 4)
Ischemic Stroke (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 1)
Lung Diseases, Interstitial (Phase 1)
Migraine Disorders (Phase 3)
Mitral Valve Stenosis (Phase 4)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 4)
Non-ST Elevated Myocardial Infarction (Phase 4)
Pancreatitis (Phase 1)
Percutaneous Coronary Intervention (Phase 4)
Pharmacokinetics (Phase 1)
Prostatic Neoplasms (Phase 1)
Pulmonary Embolism (Phase 4)
Renal Insufficiency (Phase 1)
Renal Insufficiency, Chronic (Phase 4)
Respiratory Syncytial Virus Infections (Phase 1)
Scleroderma, Systemic (Phase 1)
Secondary Prevention (Phase 3)
Staphylococcal Infections (Phase 2)
ST Elevation Myocardial Infarction (Phase 4)
Stroke (Phase 4)
Subarachnoid Hemorrhage (Phase 3)
Thromboembolism (Phase 4)
Thrombosis (Phase 4)
Vascular Diseases (Phase 4)
Venous Thromboembolism (Phase 4)
Venous Thrombosis (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
